adrenal incidentaloma
in review
5 min read
Updated 2026-11-19
adrenal incidentaloma
Defined as an adrenal mass ≥1 cm discovered on imaging performed for an unrelated indication. Every evaluation answers two questions: is it malignant? and is it hormonally active? On unenhanced CT, a homogeneous mass with ≤10 HU is benign — no repeat imaging is needed regardless of size and metanephrines are not required. Every patient gets a 1-mg overnight DST; ARR is ordered only if hypertensive or hypokalaemic. Never biopsy an adrenal mass before excluding phaeochromocytoma.
do not miss
- Biopsy before excluding phaeochromocytoma: can trigger fatal hypertensive crisis — adrenal biopsy is almost never indicated anyway (only if extra-adrenal malignancy is known, biopsy changes management, and phaeo is excluded).
- Adrenocortical carcinoma (ACC): suspect if ≥4 cm, heterogeneous, unenhanced CT >20 HU, rapid growth, or androgen/oestrogen excess — never biopsy (seeding risk); refer for complete en bloc resection.
- Perioperative adrenal crisis: patients with MACS (1-mg DST >50 nmol/L) have contralateral adrenal suppression and require perioperative stress-dose glucocorticoids during adrenalectomy.
step 1 — assess malignancy risk (ESE 2023)
Obtain a dedicated unenhanced adrenal CT if not already done (or review unenhanced attenuation on the index scan):
| unenhanced CT appearance | interpretation | imaging follow-up / action |
|---|---|---|
| homogeneous and ≤10 HU | benign lipid-rich adenoma | no further imaging (regardless of size; ESE 2023) |
| homogeneous, 11–20 HU, and <4 cm | indeterminate (usually benign lipid-poor adenoma) | immediate second-line imaging (FDG-PET/CT, MRI chemical shift, or delayed contrast washout CT) or single repeat unenhanced CT/MRI in 12 months |
| ≥4 cm with 11–20 HU, or <4 cm with >20 HU or heterogeneous | low–intermediate malignancy risk | immediate additional imaging preferred (FDG-PET/CT, MRI chemical shift, or contrast washout CT — rapid washout favours benign adenoma; slow/low delayed washout [<50–60% absolute or <40% relative at 10–15 min] suggests malignancy, though phaeochromocytomas can mimic benign washout) |
| ≥4 cm AND (heterogeneous or >20 HU) | high risk of malignancy (ACC, metastasis, phaeo) | multidisciplinary review; consider FDG-PET/CT to stage; surgery usually favoured (open if local invasion/ACC suspected) |
| growth on repeat imaging | ≥20% increase and ≥5 mm absolute diameter increase | suspicious → consider surgical resection (no change in size → no further imaging; measurable growth below threshold → consider repeat scan in 6–12 months) |
- Known active extra-adrenal malignancy: metastasis is much more likely; use FDG-PET/CT to distinguish metastasis from benign adenoma (skip biopsy unless results will change oncologic therapy and phaeo is excluded)
- Classic benign non-adenoma lesions (myelolipoma with macroscopic fat, simple cyst): require no further imaging
step 2 — assess hormonal activity (ESE 2023)
| hormone axis | who to test | screening test | threshold / action |
|---|---|---|---|
| cortisol | all patients | 1-mg overnight DST | ≤50 nmol/L excludes autonomous secretion; >50 nmol/L without overt Cushing stigmata = MACS |
| catecholamines | only if imaging is not typical of a benign lipid-rich adenoma (>10 HU or heterogeneous) | plasma free or 24-h urine fractionated metanephrines | not needed if homogeneous ≤10 HU (ESE 2023 R3.9); see phaeochromocytoma and paraganglioma |
| aldosterone | hypertension or unexplained hypokalaemia | morning seated ARR (aldosterone + renin) | see secondary hypertension for ES 2025 vs HTN Canada 2020 thresholds and AVS |
| sex steroids / precursors | clinical virilisation/feminisation or imaging suspicious for ACC | DHEA-S, androstenedione, testosterone, 17-OHP (or urine steroid metabolomics) | elevated precursors support ACC; measure pre-op |
- Bilateral adrenal incidentalomas: evaluate each lesion’s imaging features independently; perform the same hormonal panel plus screen for adrenal insufficiency (if suspected metastases, haemorrhage, lymphoma, or infiltrative disease) and congenital adrenal hyperplasia (17-OHP if bilateral hyperplasia)
mild autonomous cortisol secretion (MACS)
- Diagnosis (ESE 2023): 1-mg DST cortisol >50 nmol/L in a patient without overt clinical features of cushing syndrome (repeat 1-mg DST once to confirm; confirm ACTH-independence with suppressed/low-normal morning plasma ACTH)
- Why it matters: associated with increased prevalence of hypertension, type 2 diabetes, dyslipidaemia, osteoporosis/vertebral fractures, cardiovascular events, and mortality
- Management:
- Screen all patients with MACS for hypertension, type 2 diabetes, and vertebral fractures (DXA ± spine X-ray/VFA) and treat comorbidities aggressively
- Surgery vs conservative management: discuss laparoscopic unilateral adrenalectomy in an individualised multidisciplinary setting for patients with relevant cortisol-related comorbidities (especially younger patients or progressive/difficult-to-control HTN, T2DM, or fragility fractures)
- Perioperative protection: if resected, administer perioperative stress-dose glucocorticoids and taper post-operatively until HPA-axis recovery is confirmed (see adrenal insufficiency)
- Non-functioning benign adenoma (≤10 HU and normal hormonal workup): no routine repeat hormonal testing unless new clinical signs of hormone excess or worsening comorbidities emerge
surgical indications and biopsy rules
- Operate for:
- Hormonally active unilateral tumour (phaeochromocytoma, unilateral primary aldosteronism, overt cushing syndrome, or selected MACS with comorbidities)
- Indeterminate/suspicious mass (especially ≥4 cm with >20 HU or heterogeneity, or growth ≥20% and ≥5 mm)
- Approach: laparoscopic adrenalectomy for benign lesions and small non-invasive masses; open adrenalectomy for suspected ACC with local invasion or large invasive tumours (>6 cm) to avoid capsular rupture
- Adrenal biopsy: contraindicated for routine incidentalomas and suspected ACC; reserve strictly for patients with a history of extra-adrenal malignancy when the mass is indeterminate on imaging, phaeochromocytoma has been excluded, and tissue confirmation will directly alter management
Prepared 2026-11-19. Not yet verified — check every number against the sources.